用BNT162b2进行增强疫苗接种改善了冠状病毒疫苗接种的儿科人口的细胞和幽默免疫反应
Diego A Díaz-Dinamarca1, Simone Cárdenas-Cáceres2, Nicolás A Muena2
1Subdepartamento Innovación y Desarrollo, Departamento Agencia Nacional de Dispositivos Médicos, Innovación y Desarrollo, Instituto de Salud Pública de Chile, Santiago 7780050, Chile.
Vaccines
|August 29, 2024
概括
与单独的CoronaVac相比,用BNT162b2进行的补充疫苗显著提高了儿童对Omicron变异的免疫反应. 三剂BNT162b2提供了对SARS-CoV-2 Omicron的最强的保护.
科学领域:
- 免疫学 免疫学 免疫学
- 病毒学 病毒学
- 儿科医学 儿科医学
背景情况:
- 在全球范围内,SARS-CoV-2 Omicron变异导致了显著的儿科COVID-19住院治疗.
- 在智利,BNT162b2和CoronaVac是主要的儿科疫苗,在这个年龄组中,对基于武汉-胡-1菌株的疫苗的数据有限.
- 补充疫苗接种对于维持对新出现的SARS-CoV-2 Omicron亚系的免疫力至关重要.
研究的目的:
- 描述小儿科队列中对Omicron BA.1变异的幽默和细胞免疫反应.
- 为了比较涉及CoronaVac和BNT162b2助推剂的不同疫苗接种计划的免疫性.
- 评估10-16岁儿童异种疫苗接种策略的有效性.
主要方法:
- 一个儿科队列 (10-16岁) 接受了不同的疫苗接种计划:2剂CoronaVac,2次CoronaVac+1次BNT162b2,2次CoronaVac+2次BNT162b2,或3次BNT162b2.
- 通过对抗S1和对抗Omicron BA.1.的中和抗体标位来评估幽默免疫力.
- 通过测量特定的CD4和CD8T细胞反应来评估细胞免疫力.
主要成果:
- [CoronaVac(2x) + BNT162b2 (2x) ]方案诱导的抗S1和中和抗体标位高于单独使用2x CoronaVac.
- 在异种疫苗接种组中观察到针对Omicron的增强的CD4和CD8T细胞免疫力.
- 在接受三剂BNT162b2.2.的组中,对Omicron的免疫力最高.
结论:
- 与两个CoronaVac剂量相比,用BNT162b2进行强剂接种显著改善了儿童对Omicron的保护性免疫力.
- 不同类型的疫苗接种策略,特别是多个BNT162b2增强剂,增强了小儿对SARS-CoV-2 Omicron的免疫反应.
- 接种BNT162b2疫苗,特别是在三剂方案中,在儿童群体中提供了对Omicron的优越保护.
相关概念视频
01:51Vaccinations
44.2K
Overview
44.2K
01:36Humoral Immune Responses
72.3K
Overview
72.3K
01:29Immune Response Against Viral Pathogens
765
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
765
01:22Development of Immunocompetence
295
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
295
01:30Cancer Vaccines
347
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
347
01:40Cell-mediated Immune Responses
67.9K
Overview
67.9K